These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29436713)

  • 1. When ultrasound anomalies are present: An estimation of the frequency of chromosome abnormalities not detected by cell-free DNA aneuploidy screens.
    Reimers RM; Mason-Suares H; Little SE; Bromley B; Reiff ES; Dobson LJ; Wilkins-Haug L
    Prenat Diagn; 2018 Mar; 38(4):250-257. PubMed ID: 29436713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should cell-free DNA testing be used in pregnancy with increased fetal nuchal translucency?
    Miranda J; Paz Y Miño F; Borobio V; Badenas C; Rodriguez-Revenga L; Pauta M; Borrell A
    Ultrasound Obstet Gynecol; 2020 May; 55(5):645-651. PubMed ID: 31301176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What would be missed in the first trimester if nuchal translucency measurement is replaced by cell free DNA foetal aneuploidy screening?
    Huang LY; Pan M; Han J; Zhen L; Yang X; Li DZ
    J Obstet Gynaecol; 2018 May; 38(4):498-501. PubMed ID: 29433355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with common and atypical chromosome abnormalities after positive combined first-trimester screening in Chinese women: a retrospective cohort study.
    Mak A; Lee H; Poon CF; Kwok SL; Ma T; Chan KYK; Kan A; Tang M; Leung KY
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):55. PubMed ID: 30717698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities.
    Norton ME; Baer RJ; Wapner RJ; Kuppermann M; Jelliffe-Pawlowski LL; Currier RJ
    Am J Obstet Gynecol; 2016 Jun; 214(6):727.e1-6. PubMed ID: 26709085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial.
    Kagan KO; Sroka F; Sonek J; Abele H; Lüthgens K; Schmid M; Wagner P; Brucker S; Wallwiener D; Hoopmann M
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):437-444. PubMed ID: 28925570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perinatal outcomes following cell-free DNA screening in >32 000 women: Clinical follow-up data from a single tertiary center.
    Liang D; Lin Y; Qiao F; Li H; Wang Y; Zhang J; Liu A; Ji X; Ma D; Jiang T; Hu P; Xu Z
    Prenat Diagn; 2018 Sep; 38(10):755-764. PubMed ID: 29966040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of chromosomal abnormalities in fetuses with first trimester ultrasound anomalies and a low-risk cell-free DNA test for common trisomies.
    Persico N; Boito S; Volpe P; Ischia B; Gentile M; Ronzoni L; De Robertis V; Fabietti I; Olivieri C; Periti E; Ficarella R; Silipigni R; Rembouskos G
    Prenat Diagn; 2020 Oct; 40(11):1474-1481. PubMed ID: 33034897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester screening based on cell-free DNA vs combined screening: A randomized clinical trial on women's experience.
    Migliorini S; Saccone G; Silvestro F; Massaro G; Arduino B; D'Alessandro P; Petti MT; Paino JAC; Guida M; Locci M; Zullo F
    Prenat Diagn; 2020 Oct; 40(11):1482-1488. PubMed ID: 32683755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of 12-13-week scan for early diagnosis of fetal congenital anomalies in the cell-free DNA era.
    Kenkhuis MJA; Bakker M; Bardi F; Fontanella F; Bakker MK; Fleurke-Rozema JH; Bilardo CM
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):463-469. PubMed ID: 28397377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of fetoplacental mosaicism on cell-free DNA testing for sex chromosome aneuploidies.
    Grati FR; Bajaj K; Zanatta V; Malvestiti F; Malvestiti B; Marcato L; Grimi B; Maggi F; Simoni G; Gross SJ; Ferreira J
    Prenat Diagn; 2017 Oct; 37(10):1017-1027. PubMed ID: 28801976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of ultrasound examination at 10-14 weeks prior to cell-free DNA screening for fetal aneuploidy.
    Vora NL; Robinson S; Hardisty EE; Stamilio DM
    Ultrasound Obstet Gynecol; 2017 Apr; 49(4):465-469. PubMed ID: 27300317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
    Kagan KO; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):42-7. PubMed ID: 25307357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal and postnatal findings in small-for-gestational-age fetuses without structural ultrasound anomalies at 18-24 weeks.
    de Wit MC; Srebniak MI; Joosten M; Govaerts LC; Kornelisse RF; Papatsonis DN; de Graaff K; Knapen MF; Bruggenwirth HT; de Vries FA; Van Veen S; Van Opstal D; Galjaard RJ; Go AT
    Ultrasound Obstet Gynecol; 2017 Mar; 49(3):342-348. PubMed ID: 27102944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of ultrasound preceding cell-free DNA screening for fetal chromosomal abnormalities.
    Brown I; Fernando S; Menezes M; da Silva Costa F; Ramkrishna J; Meagher S; Rolnik DL
    Prenat Diagn; 2020 Oct; 40(11):1439-1446. PubMed ID: 32662897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry.
    Verdin SM; Whitlow BJ; Lazanakis M; Kadir RA; Chatzipapas I; Economides DL
    Ultrasound Obstet Gynecol; 2000 Oct; 16(5):402-6. PubMed ID: 11169322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical accuracy of abnormal cell-free fetal DNA results for the sex chromosomes.
    Scibetta EW; Gaw SL; Rao RR; Silverman NS; Han CS; Platt LD
    Prenat Diagn; 2017 Dec; 37(13):1291-1297. PubMed ID: 28837243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-free DNA and contingent screening: Our first year.
    Gomes HH; Lourenço I; Ribeiro J; Martins D; Ribeiro R; Francisco C
    J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):509-514. PubMed ID: 30951890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.